The treatment of chronic insomnia: Drug indications, chronic use and abuse liability. Summary of a 2001 New Clinical Drug Evaluation unit Meeting Sympoium

Wallace B. Mendelson, Thomas Roth, James Cassella, Timothy Roehrs, James K. Walsh, James H. Woods, Daniel J. Buysse, Roger E. Meyer

Research output: Contribution to journalArticle

110 Citations (Scopus)

Abstract

This paper summarizes a group of presentations and panel discussions on chronic insomnia at the 2001 NCDEU meeting. The presentations and discussions focused on the twin issues of efficacy and concerns of abuse liability with long-term hypnotic therapy. The panel concluded that insomnia may be an epidemiological marker for a variety of difficulties including accidents, increased health care utilization and subsequent development of major depression. Whether or not treatment of insomnia will prevent these long-term problems has not yet been determined. Since the mid-1980s there has been a rapid rise in the off-label use of antidepressants, particularly trazodone, for treating insomnia. Some participants expressed concern at the lack of data for this practice, particularly the absence of dose-response and tolerance information, and noted that the small amount of efficacy data available is not encouraging. Similarly, there are minimal data to support the use of antihistamines as sleep aids; moreover, their side effect profile and interactions with other drugs may be under appreciated. The limited data available on nightly long-term usage of the newer non-benzodiazepine hypnotics, primarily of six-months' duration, suggest an absence of tolerance, but more data for both nightly and non-nightly administration are needed. Insomniacs tend to show therapy-seeking, rather than drug-seeking behavior, and patients without histories of drug abuse are unlikely to self-escalate dosage of currently available hypnotics. There is fairly good agreement on the characteristics of an ideal hypnotic. All currently available agents, while effective and safe, do not achieve this ideal. The next few years are likely to see the appearance of a variety of agents with new and promising mechanisms of action.

Original languageEnglish (US)
Pages (from-to)7-17
Number of pages11
JournalSleep Medicine Reviews
Volume8
Issue number1
DOIs
StatePublished - Feb 2004

Fingerprint

Drug Evaluation
Sleep Initiation and Maintenance Disorders
Hypnotics and Sedatives
Pharmaceutical Preparations
Patient Acceptance of Health Care
Drug-Seeking Behavior
Trazodone
Off-Label Use
Histamine Antagonists
Therapeutics
Antidepressive Agents
Substance-Related Disorders
Accidents
Sleep
Depression

All Science Journal Classification (ASJC) codes

  • Pulmonary and Respiratory Medicine
  • Neurology
  • Clinical Neurology
  • Physiology (medical)

Cite this

Mendelson, Wallace B. ; Roth, Thomas ; Cassella, James ; Roehrs, Timothy ; Walsh, James K. ; Woods, James H. ; Buysse, Daniel J. ; Meyer, Roger E. / The treatment of chronic insomnia : Drug indications, chronic use and abuse liability. Summary of a 2001 New Clinical Drug Evaluation unit Meeting Sympoium. In: Sleep Medicine Reviews. 2004 ; Vol. 8, No. 1. pp. 7-17.
@article{fabc619f590b42dd838838fb2f32f234,
title = "The treatment of chronic insomnia: Drug indications, chronic use and abuse liability. Summary of a 2001 New Clinical Drug Evaluation unit Meeting Sympoium",
abstract = "This paper summarizes a group of presentations and panel discussions on chronic insomnia at the 2001 NCDEU meeting. The presentations and discussions focused on the twin issues of efficacy and concerns of abuse liability with long-term hypnotic therapy. The panel concluded that insomnia may be an epidemiological marker for a variety of difficulties including accidents, increased health care utilization and subsequent development of major depression. Whether or not treatment of insomnia will prevent these long-term problems has not yet been determined. Since the mid-1980s there has been a rapid rise in the off-label use of antidepressants, particularly trazodone, for treating insomnia. Some participants expressed concern at the lack of data for this practice, particularly the absence of dose-response and tolerance information, and noted that the small amount of efficacy data available is not encouraging. Similarly, there are minimal data to support the use of antihistamines as sleep aids; moreover, their side effect profile and interactions with other drugs may be under appreciated. The limited data available on nightly long-term usage of the newer non-benzodiazepine hypnotics, primarily of six-months' duration, suggest an absence of tolerance, but more data for both nightly and non-nightly administration are needed. Insomniacs tend to show therapy-seeking, rather than drug-seeking behavior, and patients without histories of drug abuse are unlikely to self-escalate dosage of currently available hypnotics. There is fairly good agreement on the characteristics of an ideal hypnotic. All currently available agents, while effective and safe, do not achieve this ideal. The next few years are likely to see the appearance of a variety of agents with new and promising mechanisms of action.",
author = "Mendelson, {Wallace B.} and Thomas Roth and James Cassella and Timothy Roehrs and Walsh, {James K.} and Woods, {James H.} and Buysse, {Daniel J.} and Meyer, {Roger E.}",
year = "2004",
month = "2",
doi = "10.1016/S1087-0792(03)00042-X",
language = "English (US)",
volume = "8",
pages = "7--17",
journal = "Sleep Medicine Reviews",
issn = "1087-0792",
publisher = "W.B. Saunders Ltd",
number = "1",

}

The treatment of chronic insomnia : Drug indications, chronic use and abuse liability. Summary of a 2001 New Clinical Drug Evaluation unit Meeting Sympoium. / Mendelson, Wallace B.; Roth, Thomas; Cassella, James; Roehrs, Timothy; Walsh, James K.; Woods, James H.; Buysse, Daniel J.; Meyer, Roger E.

In: Sleep Medicine Reviews, Vol. 8, No. 1, 02.2004, p. 7-17.

Research output: Contribution to journalArticle

TY - JOUR

T1 - The treatment of chronic insomnia

T2 - Drug indications, chronic use and abuse liability. Summary of a 2001 New Clinical Drug Evaluation unit Meeting Sympoium

AU - Mendelson, Wallace B.

AU - Roth, Thomas

AU - Cassella, James

AU - Roehrs, Timothy

AU - Walsh, James K.

AU - Woods, James H.

AU - Buysse, Daniel J.

AU - Meyer, Roger E.

PY - 2004/2

Y1 - 2004/2

N2 - This paper summarizes a group of presentations and panel discussions on chronic insomnia at the 2001 NCDEU meeting. The presentations and discussions focused on the twin issues of efficacy and concerns of abuse liability with long-term hypnotic therapy. The panel concluded that insomnia may be an epidemiological marker for a variety of difficulties including accidents, increased health care utilization and subsequent development of major depression. Whether or not treatment of insomnia will prevent these long-term problems has not yet been determined. Since the mid-1980s there has been a rapid rise in the off-label use of antidepressants, particularly trazodone, for treating insomnia. Some participants expressed concern at the lack of data for this practice, particularly the absence of dose-response and tolerance information, and noted that the small amount of efficacy data available is not encouraging. Similarly, there are minimal data to support the use of antihistamines as sleep aids; moreover, their side effect profile and interactions with other drugs may be under appreciated. The limited data available on nightly long-term usage of the newer non-benzodiazepine hypnotics, primarily of six-months' duration, suggest an absence of tolerance, but more data for both nightly and non-nightly administration are needed. Insomniacs tend to show therapy-seeking, rather than drug-seeking behavior, and patients without histories of drug abuse are unlikely to self-escalate dosage of currently available hypnotics. There is fairly good agreement on the characteristics of an ideal hypnotic. All currently available agents, while effective and safe, do not achieve this ideal. The next few years are likely to see the appearance of a variety of agents with new and promising mechanisms of action.

AB - This paper summarizes a group of presentations and panel discussions on chronic insomnia at the 2001 NCDEU meeting. The presentations and discussions focused on the twin issues of efficacy and concerns of abuse liability with long-term hypnotic therapy. The panel concluded that insomnia may be an epidemiological marker for a variety of difficulties including accidents, increased health care utilization and subsequent development of major depression. Whether or not treatment of insomnia will prevent these long-term problems has not yet been determined. Since the mid-1980s there has been a rapid rise in the off-label use of antidepressants, particularly trazodone, for treating insomnia. Some participants expressed concern at the lack of data for this practice, particularly the absence of dose-response and tolerance information, and noted that the small amount of efficacy data available is not encouraging. Similarly, there are minimal data to support the use of antihistamines as sleep aids; moreover, their side effect profile and interactions with other drugs may be under appreciated. The limited data available on nightly long-term usage of the newer non-benzodiazepine hypnotics, primarily of six-months' duration, suggest an absence of tolerance, but more data for both nightly and non-nightly administration are needed. Insomniacs tend to show therapy-seeking, rather than drug-seeking behavior, and patients without histories of drug abuse are unlikely to self-escalate dosage of currently available hypnotics. There is fairly good agreement on the characteristics of an ideal hypnotic. All currently available agents, while effective and safe, do not achieve this ideal. The next few years are likely to see the appearance of a variety of agents with new and promising mechanisms of action.

UR - http://www.scopus.com/inward/record.url?scp=1542329142&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1542329142&partnerID=8YFLogxK

U2 - 10.1016/S1087-0792(03)00042-X

DO - 10.1016/S1087-0792(03)00042-X

M3 - Article

C2 - 15062207

AN - SCOPUS:1542329142

VL - 8

SP - 7

EP - 17

JO - Sleep Medicine Reviews

JF - Sleep Medicine Reviews

SN - 1087-0792

IS - 1

ER -